ROIV · CIK 1635088
What Roivant Sciences Ltd told the SEC could break it.
Roivant's risks center on a manufacturing supply chain it doesn't own and can't fully control. It and its 'Vant' subsidiaries have no manufacturing of their own and rely on third-party CMOs, plus a limited number of — and in some cases single or sole — sources for product components, with no qualified backups, creating real supply-interruption risk for their candidates. That outsourced chain runs into two new policy threats: the BIOSECURE Act, enacted in December 2025, which targets biotech ties to certain foreign adversaries and could disrupt its CMO relationships; and Section 232 pharmaceutical tariffs of 10% to 100% on drugs, APIs and key starting materials, announced in April 2026 and effective that September, which could raise its manufacturing input costs depending on product type and country of origin.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- Section 232 pharmaceutical tariffs (10%-100%, effective Sept 2026)medium
Section 232 national-security tariffs of 10%-100% on pharmaceutical products, APIs and key starting materials (announced April 2026, effective September 2026) threaten to raise Roivant's manufacturing input costs depending on product type and country of origin.
“On April 2, 2026, the United States announced significant tariffs on certain pharmaceutical products, active pharmaceutical ingredients and key starting materials. These tariffs, which were imposed pursuant to a national security investigation under Section 232 of the Trade Expansion Act of 1962, will generally go into effect in September 2026. The tariffs, which range from 10% to 100% depending on type of product and country of origin, are also subject to a number of exemptions and exclusions.”
SEC filing →As of 2026 - BIOSECURE Act (Dec 2025) restricting ties to foreign-adversary CMOsmedium
The BIOSECURE Act, enacted December 2025, targets biotech companies with ties to certain foreign adversaries; because Roivant and its Vants rely on third-party CMOs for drug substance and product, the law could disrupt their manufacturing supply chain.
“Legislation targeting biotechnology companies with ties to certain foreign adversaries, including the BIOSECURE Act, could materially adversely affect our business, supply chain and results of operations. We and certain of our Vants rely on third-party contract manufacturing organizations (“CMOs”) to manufacture drug substance and drug product for our product candidates.”
Sole-source dependency
- single/sole-source product components; no own manufacturing (CMO reliance)medium
Roivant has no manufacturing of its own and depends on a limited number of — and in some cases single/sole — sources for product components, with a lack of qualified backup suppliers, creating supply-interruption risk for its product candidates.
“reliance on a limited number of sources, and in some cases, single sources for product components, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell our product candidates following regulatory approval in a timely fashion, in sufficient quantities or under acceptable terms; lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier;”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch